In vitro maturation with letrozole priming: Can it be a solution for patients with cancerophobia? A pilot study

Basit Öğe Kaydı
dc.contributor.authorHatirnaz, Safak
dc.contributor.authorHatirnaz, Ebru Saynur
dc.contributor.authorBasbug, Alper
dc.contributor.authorPektas, Mine Kanat
dc.contributor.authorErol, Onur
dc.contributor.authorDahan, Michael
dc.contributor.authorTan, Seang
dc.date.accessioned2021-12-01T18:50:30Z
dc.date.available2021-12-01T18:50:30Z
dc.date.issued2020
dc.department[Belirlenecek]en_US
dc.description.abstractObjective: To investigate whether letrozole priming could be used efficiently in patients undergoing in vitro maturation (IVM) as compared with follicle-stimulating hormone (FSH) priming. Materials and Methods: This is a retrospective analysis of 63 patients who underwent IVM due to the high risk of Ovarian Hyperstimulation syndrome (OHSS) (n=39), cancerophobia (n=16), and desire for IVM after failed in vitro fertilization attempts (n=8). Forty-two patients received FSH priming and 21 patients received letrozole priming. Results: The patients who had FSH or letrozole priming were statistically similar with respect to age, body mass index, duration of infertility, basal antral follicle count, serum anti-Mullerian hormone levels, and IVM indications (p>0.05 for all). When compared with the FSH priming group, the number of germinal vesicle oocytes, metaphase 11 and fertilized oocytes were significantly higher (p=0.003, p=0.001, and p=0.016, respectively), but the number of metaphase I oocytes was significantly lower in the letrozole priming group (p=0.002). The patients who received FSH and letrozole priming had statistically similar rates of implantation (33.3% vs 37.0%, p=0.709), clinical pregnancy (31.5% vs 33.3%, p=0.848), twinning (1.9% vs 3.7%, p=0.611), and live birth (24.1% vs 29.6%, p=0.682). Conclusion: Potential indications for IVM include patients with increased risk for OHSS and contraindication for hyperestrogenism. Aromatase inhibitors can be used to preserve the fertility of patients with estrogen-sensitive cancers. Letrozole priming appears to be an efficient approach in patients who undergo IVM, with likely less cost than FSH priming.en_US
dc.identifier.doi10.4274/tjod.galenos.2020.79446
dc.identifier.endpage252en_US
dc.identifier.issn2149-9322
dc.identifier.issn2149-9330
dc.identifier.issue4en_US
dc.identifier.pmid33343970en_US
dc.identifier.scopus2-s2.0-85109864641en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage247en_US
dc.identifier.urihttps://doi.org/10.4274/tjod.galenos.2020.79446
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10887
dc.identifier.volume17en_US
dc.identifier.wosWOS:000598157300003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal Of Obstetrics And Gynecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCancerphobiaen_US
dc.subjectin vitro maturation techniquesen_US
dc.subjectletrozoleen_US
dc.subjectoocytesen_US
dc.subjectOvarian Hyperstimulation syndromeen_US
dc.subjectpregnancyen_US
dc.subjectSingle-Embryo Transferen_US
dc.subjectPolycystic Ovariesen_US
dc.subjectOocyte Maturationen_US
dc.subjectDefinitionen_US
dc.subjectIvmen_US
dc.titleIn vitro maturation with letrozole priming: Can it be a solution for patients with cancerophobia? A pilot studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10887.pdf
Boyut:
124.32 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu